Menu
Live News EQUITY H impact

TCRX: Reports Positive Data

TScan Therapeutics announces positive initial data from cohort C of ongoing ALLOHA Phase 1 study evaluating TSC-101

TCRX

TCRX - TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation